Form 8-K - Current report:
SEC Accession No. 0001558370-25-000641
Filing Date
2025-02-05
Accepted
2025-02-05 08:30:18
Documents
16
Period of Report
2025-02-05
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K apre-20250205x8k.htm   iXBRL 8-K 39037
2 EX-99.1 apre-20250205xex99d1.htm EX-99.1 13426
3 GRAPHIC apre-20250205xex99d1002.jpg GRAPHIC 8841
  Complete submission text file 0001558370-25-000641.txt   194838

Data Files

Seq Description Document Type Size
4 EX-101.SCH apre-20250205.xsd EX-101.SCH 4087
5 EX-101.DEF apre-20250205_def.xml EX-101.DEF 2842
6 EX-101.LAB apre-20250205_lab.xml EX-101.LAB 16591
7 EX-101.PRE apre-20250205_pre.xml EX-101.PRE 10901
18 EXTRACTED XBRL INSTANCE DOCUMENT apre-20250205x8k_htm.xml XML 4631
Mailing Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902
Business Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902 617-463-9385
Aprea Therapeutics, Inc. (Filer) CIK: 0001781983 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39069 | Film No.: 25590990
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)